Dani Bancroft, Author at Labiotech.eu

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

kasios bone therapeutics 3D print osteoporosis

News and Trends 2 Feb 2016

From Belgium: 3D-Bioprinted ‘Waffle’ to Fix Broken Bones

Bone Therapeutics (Belgium) is a cell therapy biotech working on bone fracture repair which has now extended its collaboration with Kasios (France), to develop next-generation bone disease therapy with 3D-Bioprinting technology. The current standard-of-care in the Bones field involves major surgeries and (consequently) long recovery time. Bone Therapeutics is, therefore, developing a range of regenerative products containing osteoblasts (bone-forming cells), which […]

February 2, 2016 - 3 minutesmins - By Dani Bancroft

medicxi venture index fund uk genmab jjdc gsk fund

News and Trends 2 Feb 2016

New €210M Life Sciences Fund is Launched in UK

Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210M Fund including GSK and Johnson & Johnson Innovation. Medicxi Ventures is based in London, Geneva and Jersey and has been investing in the Life Sciences field for over 20 years. It comprises all of the legacy portfolio […]

February 2, 2016 - 2 minutesmins - By Dani Bancroft

microalgae biotech biofuels medicine scrubbing greentech review

In Depth 2 Feb 2016

The Unlimited Biotech Potential of Algae

Is the Future of Biotech…Green? The Algae Industry ranges from Biofuels to Nutrition to Fashion and Microalgae hold lots of potential for the industry to expand. But why? And do Venture Capitalists agree? Microalgae have already been established as incredibly valuable to the biotech industry, in part due to their ancient genetic diversity and resilience, providing […]

February 2, 2016 - 9 minutesmins - By Dani Bancroft

msd cancer research uk monash crt merck australia

News and Trends 1 Feb 2016

New Discovery unites Australia, Germany and UK Against Blood Cancers

Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network. The Australian Co-operative Research Centre (CRC) for Cancer Therapeutics (CTx) in Melbourne has a range of investigational inhibitors for blood disorders – including Leukemia. CTx is collaborative partnership […]

February 1, 2016 - 2 minutesmins - By Dani Bancroft

pei ying lin smallpox syndrome bioart uk

News and Trends 29 Jan 2016

Pei-Ying Lin’s BioArt: Stunning Smallpox, Nutritious NanoFood and Microbial Fractals

Pei-Ying Lin founded the Taiwanese BioArt community with her Science-Humanities and programming background to tackle complex BioArt statements all across the EU. Lin is a Scientist-turned-artist, with her fascination in BioArt having stemmed from a Life Sciences degree from the National Tsing Hua University in Taiwan and a Masters at the Royal College of Art in London. She’s also […]

January 29, 2016 - 2 minutesmins - By Dani Bancroft

karolinska microbiome ferring pharma research scilifelab

News and Trends 28 Jan 2016

Sweden and Switzerland Join in on Microbiome Hype with New Karolinska Research Centre

Ferring Pharmaceuticals (Switzerland) and the Karolinska Institutet (Sweden) announce a collaboration on a new research centere exploiting the human microbiome. The Karolinska Institutet has a deep understanding of the human microbiome, and the institute actually accounts for over 40% of the medical academic research conducted in Sweden (not to mention their long-standing ties with the Nobel Prize […]

January 28, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

Twist dna bioscience sequencing micrarray emily leproust

News and Trends 27 Jan 2016

French Investor Leads €60M Financial Round for the Future of DNA Synthesis

Twist Bioscience is a San Francisco Biotech accelerating science and innovation through rapid, high-quality DNA synthesis piece of tech. And now, Twist has completed a $61 million Series D round. An improved silicon-based design compared to the traditional 96-well plates could do wonders for DNA synthesis, including major improvements in cost and time of the process. And the […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

cambridge gsk ucl imperial apollo jj astrazeneca

News and Trends 27 Jan 2016

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge. This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck’s (MSD) anti-PD-1 therapy (Keytruda), with Affimed’s proprietary drug for the treatment of patients with Hodgkin lymphoma. The phase Ib trial will focus on patients whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

galapags ulcerative colitis gilead trials

News and Trends 26 Jan 2016

Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure

Galapagos (Belgium) and Gilead (US) announced today the closing and entry into force of their global license and collaboration agreement on filgotinib, just as results are released for a phase II trial against Ulcerative colitis. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $300M by Gilead […]

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Jan 2016

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Immunocore in Oxford (UK) has been Granted Orphan Drug Designation for a Phase I Super rare Eye cancer drug by the FDA. Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, […]

January 25, 2016 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dani Bancroft

About

Articles by Dani Bancroft

From Belgium: 3D-Bioprinted ‘Waffle’ to Fix Broken Bones

New €210M Life Sciences Fund is Launched in UK

The Unlimited Biotech Potential of Algae

New Discovery unites Australia, Germany and UK Against Blood Cancers

Pei-Ying Lin’s BioArt: Stunning Smallpox, Nutritious NanoFood and Microbial Fractals

Sweden and Switzerland Join in on Microbiome Hype with New Karolinska Research Centre

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

French Investor Leads €60M Financial Round for the Future of DNA Synthesis

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure

This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Dani Bancroft

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!